Status: Recruiting
Ivonescimab for the Treatment of Thymic Cancer
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Jonsson Comprehensive Cancer CenterUpdated: Jun 1, 2026Locations: 5
Eligibility criteria
Male or female ≥ 18 years of age and willing and able to provide informed consen... [+22]
Prior treatment with an immune checkpoint inhibitor targeted PD-1 or PD-L1. Prio... [+38]